Additional file 8 of The MYC/TXNIP axis mediates NCL-Suppressed CD8+T cell immune response in lung adenocarcinoma

Supplementary Material 8: Figure S8. Impact of NCL Targeting the MYC/TXNIP Axis on In Vivo Anti-Tumor Immunity and Glycolytic Activity in CD8+ T Cells. Notes: (A) Morphology images of tumor tissues in mice from each group along with volumetric analysis of tumor tissue; (B) Immunohistochemical staining images (Ki67) of tumor tissues in mice from each group, scale bar = 50 µm, and proportional analysis of Ki67-positive cells; (C) In vivo near-infrared imaging of mice 6 hours after the intratumoral injection of CD8+ T cells; (D) Semi-quantitative analysis of CD8+ T cell signals in tumors; (E-F) Ex vivo imaging of tumors 24 hours post tail vein injection of CD8+ T cells (E), with semi-quantitative CD8+ T cell signal analysis in tumors (F); (G) Measurement of serum IFN-γ levels in mice using ELISA; (H) Flow cytometry analysis of the percentage of IFN-γ-positive cells in CD8+ T cells within the tumors of mice and bar chart statistics; (I) Flow cytometry analysis of the percentage of IFN-γ-positive cells in CD8+ T cells within the spleens of mice and bar chart statistics; (J) 18F-FDG PET/CT imaging of mice from each group; (K) Quantitative analysis of SUVmax in each group; (L) RT-qPCR analysis of the expression levels of GLUT1, GLUT4, HK2, LDHA, and LDHB in CD8+ T cells from each group. * denotes statistical significance at P < 0.05, ** at P < 0.01, and *** at P < 0.001, with 5 mice per group.